Clinical trials: Severe COVID-19 Pneumonia
SARS-CoV-2
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
The goal of this study is to assess the adverse events in the acute phase observed after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation…
- Trial name
- NCT05894525
- Where
- Japan
- Volunteers
- 8,844 people
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2 (COVID-19) Severe Pneumonia
Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19
To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.
- Trial name
- NCT04412668
- Testing
- Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- aTyr Pharma, Inc.
Covid19 Pneumonia
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS
A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19
- Trial name
- NCT04569227
- Testing
- EC-18
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Enzychem Lifesciences Corporation
COVID-19
A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
The purpose of this clinical trial is to learn about how study medicine (Paxlovid, which contains nirmatrelvir and ritonavir) is changed and eliminated from the body, as well as its safety, and the extent to which side effects…
- Trial name
- NCT05386472
- Testing
- nirmatrelvir, ritonavir
- Where
- 13 sites in United States
- Volunteers
- 25 people
- Sponsor
- Pfizer
COVID-19, Coronavirus Infections
Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a
VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronaviruses: SARS-CoV-2 (the virus that causes COVID-19 disease), SARS-CoV-1 and…
- Trial name
- NCT05548439
- Testing
- VBI-2901a
- Where
- 7 sites in Canada
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
COVID-19
Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from…
- Trial name
- NCT04295551
- Testing
- Lopinavir / ritonavir tablets combined with Xiyanping injection, Lopinavir/ritonavir treatment
- Volunteers
- 80 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
COVID-19
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults.
- Trial name
- NCT04661839
- Testing
- COVID-HIGIV
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
COVID-19, COVID-19 (SARS-CoV-2 Infection)
Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of allogeneic SARS-CoV-2-Specific T cells (LB-DTK-COV19) in patients with persistent clinical symptoms following a positive SARS-CoV-2 PCR test…
- Trial name
- NCT07709637
- Testing
- LB-DTK-COV19
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- LucasBio
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
This trial consisted of three parts, Part A, Part B, and Part C, and evaluated the safety and immunogenicity of a third (booster) injection of the multivalent vaccine BNT162b2 (B.1.1.7 + B.1.617.2), and the safety and…
- Conditions
- SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
- Trial name
- NCT05004181
- Testing
- BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7)
- Where
- 35 sites in United States, Germany and 2 more
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Hemoperfusion Efferon СT for the Extremely Severe Form of COVID-19
The development of acute respiratory and renal failure of COVID-19 patients is associated with an excessive immune response and hyperproduction of anti-inflammatory cytokines, which leads to impaired endothelial function and a…
- Trial name
- NCT06402279
- Testing
- Efferon CT therapy
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Efferon JSC
Coronavirus Disease 2019 (COVID-19)
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in…
- Trial name
- PREVENT-HD (NCT04508023)
- Testing
- Rivaroxaban, Standard of Care (SOC)
- Where
- 17 sites in United States
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
Severe Acute Respiratory Syndrome Coronavirus 2
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection
Safety and efficacy of ADR-001 are evaluated in Patients with Severe Pneumonia caused by SARS-CoV-2 infection.
- Trial name
- COVID-19 (NCT04522986)
- Testing
- Mesenchymal stem cell
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
Covid19, Corona Virus Infection
Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC)…
- Conditions
- Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS
- Trial name
- ULSC (NCT04494386)
- Testing
- Umbilical Cord Lining Stem Cells (ULSC)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Restem, LLC.
COVID19
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Trial name
- NCT05175690
- Testing
- Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 1,126 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
COVID-19 Pneumonia
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19…
- Trial name
- COVACTA (NCT04320615)
- Testing
- Tocilizumab (TCZ)
- Where
- 62 sites in United States, Canada and 7 more
- Volunteers
- 452 people
- Sponsor
- Hoffmann-La Roche
COVID-19
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if Liquid Alpha1-Proteinase Inhibitor (Human) (Liquid Alpha1-PI) plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day…
- Trial name
- NCT04547140
- Testing
- Liquid Alpha1-Proteinase Inhibitor (Human), Standard Medical Treatment
- Where
- 20 sites in United States, Brazil and 3 more
- Volunteers
- 57 people
- Sponsor
- Grifols Therapeutics LLC
COVID-19
Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness
The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective for treatment of mild COVID-19 illness. Adults and adolescent participants will be followed for approximately 28 days.
- Trial name
- NCT05157269
- Testing
- Nitazoxanide, Vitamin Super-B Complex
- Sponsor
- Romark Laboratories L.C.
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
COVID-19, Coronavirus
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- COViNOX (NCT04421508)
- Testing
- INOpulse
- Where
- 17 sites in United States
- Volunteers
- 191 people
- Sponsor
- Bellerophon Pulse Technologies
COVID-19
Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)
The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney…
- Trial name
- REDPINE (NCT04745351)
- Testing
- Remdesivir, Standard of Care
- Where
- 63 sites in United States, Brazil and 4 more
- Volunteers
- 249 people
- Sponsor
- Gilead Sciences